help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dunfield, L. D.
Right arrow Articles by Nachtigal, M. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunfield, L. D.
Right arrow Articles by Nachtigal, M. W.
Endocrinology Vol. 143, No. 4 1174-1181
Copyright © 2002 by The Endocrine Society


CANCER

TGFß-Induced Smad Signaling Remains Intact in Primary Human Ovarian Cancer Cells

Lesley D. Dunfield, Elizabeth J. Campbell Dwyer and Mark W. Nachtigal

Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4H7

Address all correspondence and requests for reprints to: Mark W. Nachtigal, Dalhousie University, Department of Pharmacology, Tupper Medical Building, Halifax, Nova Scotia, Canada B3H 4H7. E-mail: . mnachtig{at}is.dal.ca

Disruptions in TGFß signaling have been implicated in various human cancers, including ovarian cancer. Our goal was to determine whether ovarian cancer cells isolated from patient ascites fluid were growth inhibited by TGFß1 treatment and further characterize the expression and activity profile of TGFß/Smad signaling components in human ovarian cancer cells. We found that 9 of 10 primary cultures of ovarian cancer cells (OC2–10) were growth inhibited by 16 pM TGFß1. One primary ovarian cancer sample (OC1) and the established ovarian cancer cell lines CaOV3 and SkOV3 continued to grow in the presence of TGFß1. All cells expressed components of the TGFß/Smad signaling pathway including TGFß1, TßRI, TßRII, Smad2, -3, -4, and Smad anchor for receptor activation. Although OC1, CaOV3, and SkOV3 are not growth inhibited by TGFß1, they can transmit the TGFß1 signal to turn on a transfected TGFß/Smad reporter gene, p3TP.lux. In addition, all cells up-regulate the endogenous TGFß target genes Smad7 and PAI-1. p15Ink4B mRNA is also up-regulated with TGFß1 treatment in OC2–9, whereas the p15Ink4B gene has been deleted in OC1, CaOV3, and SkOV3 cells. Homozygous deletion of p15Ink4B may account for TGFß resistance in some populations of ovarian cancer cells. Our data demonstrate that the TGFß/Smad signaling pathway remains functional in human ovarian cancer cells and suggest that if abnormalities exist in the cellular response of TGFß signals, they must lie downstream of the Smad proteins.




This article has been cited by other articles:


Home page
Cancer Res.Home page
J. S. Sunde, H. Donninger, K. Wu, M. E. Johnson, R. G. Pestell, G. S. Rose, S. C. Mok, J. Brady, T. Bonome, and M. J. Birrer
Expression Profiling Identifies Altered Expression of Genes That Contribute to the Inhibition of Transforming Growth Factor-{beta} Signaling in Ovarian Cancer.
Cancer Res., September 1, 2006; 66(17): 8404 - 8412.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
G. Xu, H. Zhou, Q. Wang, N. Auersperg, and C. Peng
Activin Receptor-Like Kinase 7 Induces Apoptosis through Up-Regulation of Bax and Down-Regulation of Xiap in Normal and Malignant Ovarian Epithelial Cell Lines
Mol. Cancer Res., April 1, 2006; 4(4): 235 - 246.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. N. Kloth, G. J. Fleuren, J. Oosting, R. X. de Menezes, P. H.C. Eilers, G. G. Kenter, and A. Gorter
Substantial changes in gene expression of Wnt, MAPK and TNF{alpha} pathways induced by TGF-{beta}1 in cervical cancer cell lines
Carcinogenesis, September 1, 2005; 26(9): 1493 - 1502.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J.-S. Kim, S. J. Baek, T. Sali, and T. E. Eling
The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15
Mol. Cancer Ther., March 1, 2005; 4(3): 487 - 493.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. D'Andrilli, C. Kumar, G. Scambia, and A. Giordano
Cell Cycle Genes in Ovarian Cancer: Steps Toward Earlier Diagnosis and Novel Therapies
Clin. Cancer Res., December 15, 2004; 10(24): 8132 - 8141.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. Xu, Y. Zhong, S. Munir, B. B. Yang, B. K. Tsang, and C. Peng
Nodal Induces Apoptosis and Inhibits Proliferation in Human Epithelial Ovarian Cancer Cells via Activin Receptor-Like Kinase 7
J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5523 - 5534.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. G. Shepherd and M. W. Nachtigal
Identification of a Putative Autocrine Bone Morphogenetic Protein-Signaling Pathway in Human Ovarian Surface Epithelium and Ovarian Cancer Cells
Endocrinology, August 1, 2003; 144(8): 3306 - 3314.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
Y. Fu, E. J. Campbell, T. G. Shepherd, and M. W. Nachtigal
Epigenetic Regulation of Proprotein Convertase PACE4 Gene Expression in Human Ovarian Cancer Cells
Mol. Cancer Res., June 1, 2003; 1(8): 569 - 576.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society